How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

9,078 results for

Erythropoietin

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. The hypoxia inducible factor/erythropoietin (EPO)/EPO receptor pathway is disturbed in a rat model of chronic kidney disease related anemia. Full Text available with Trip Pro

The hypoxia inducible factor/erythropoietin (EPO)/EPO receptor pathway is disturbed in a rat model of chronic kidney disease related anemia. Anemia is a known driver for hypoxia inducible factor (HIF) which leads to increased renal erythropoietin (EPO) synthesis. Bone marrow (BM) EPO receptor (EPOR) signals are transduced through a JAK2-STAT5 pathway. The origins of anemia of chronic kidney disease (CKD) are multifactorial, including impairment of both renal EPO synthesis as well as intestinal (...) iron absorption. We investigated the HIF- EPO- EPOR axis in kidney, BM and proximal tibia in anemic juvenile CKD rats.CKD was induced by 5/6 nephrectomy in young (20 days old) male Sprague-Dawley rats while C group was sham operated. Rats were sacrificed 4 weeks after CKD induction and 5 minutes after a single bolus of IV recombinant human EPO. An additional control anemic (C-A) group was daily bled for 7 days.Hemoglobin levels were similarly reduced in CKD and C-A (11.4 ± 0.3 and 10.8±0.2 Vs 13.5

2018 PLoS ONE

2. Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy

transfusions may potentially include a limited supply of blood, iron overload, immune injury, and viral and bacterial infections. Epoetin alfa, epoetin beta and darbepoetin alfa for cancer treatment-induced anaemia (NICE technology appraisal guidance 142) recommends erythropoietin analogues plus intravenous iron as an option for managing cancer treatment-induced anaemia in women having platinum-based chemotherapy for ovarian cancer and who have symptoms associated with anaemia and a haemoglobin (...) concentration of 80 g/litre or lower. Clinicians may Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (TA323) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 5 of 47also consider erythropoietin analogues for people who cannot have blood transfusions and who have profound cancer treatment-related anaemia that is likely to affect survival

2014 National Institute for Health and Clinical Excellence - Technology Appraisals

3. Aranesp (darbepoetin alfa)

, the in Aranesp, acts exactly like a natural hormone called erythropoietin that is made by the kidneys to stimulate red blood cell production, but it is very slightly different in its structure. This means that darbepoetin alfa has a longer duration of action, and can be given less often than natural erythropoietin. By acting in the same way as erythropoietin, Aranesp stimulates the body to make more red blood cells and so treats anaemia. What did the company present to support its application? The applicant (...) Aranesp (darbepoetin alfa) Aranesp: Withdrawn application | European Medicines Agency Search Search Menu Aranesp: Withdrawal of the application to change the darbepoetin alfa Table of contents Overview On 21 February 2018, Amgen Europe B.V. officially notified the ( ) that it wished to withdraw its application to add treatment of anaemia in adult patients with myelodysplastic syndromes to the existing . Expand section Collapse section What is Aranesp? Aranesp is a medicine already used to treat

2018 European Medicines Agency - EPARs

4. Epoetin alfa (Eprex) - treatment of symptomatic anaemia (haemoglobin concentration of ?10g/dL) in adults with low- or intermediate-1-risk primary myelodysplastic syndromes (MDS)

Epoetin alfa (Eprex) - treatment of symptomatic anaemia (haemoglobin concentration of ?10g/dL) in adults with low- or intermediate-1-risk primary myelodysplastic syndromes (MDS) Published 11 March 2019 Statement of advice SMC2164 epoetin alfa 2,000 / 4,000 / 10,000 / 40,000 international units per mL solution for injection in pre-filled syringe (Eprex®) Janssen-Cilag Limited 8 February 2019 ADVICE: in the absence of a submission from the holder of the marketing authorisation epoetin alfa (Eprex (...) ®) is not recommended for use within NHSScotland. Indication under review: treatment of symptomatic anaemia (haemoglobin concentration of =1 0g/ dL) in adults with low- or intermediate-1-risk primary myelodysplastic syndromes (MDS) who have low serum erythropoietin (<200 mU/mL). The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland. Advice context: No part of this advice may

2019 Scottish Medicines Consortium

5. Generation of transgenic chickens expressing the human erythropoietin (hEPO) gene in an oviduct-specific manner: Production of transgenic chicken eggs containing human erythropoietin in egg whites. Full Text available with Trip Pro

Generation of transgenic chickens expressing the human erythropoietin (hEPO) gene in an oviduct-specific manner: Production of transgenic chicken eggs containing human erythropoietin in egg whites. The transgenic chicken has been considered as a prospective bioreactor for large-scale production of costly pharmaceutical proteins. In the present study, we report successful generation of transgenic hens that lay eggs containing a high concentration of human erythropoietin (hEPO) in the ovalbumin

2018 PLoS ONE

6. EPREX (epoetin alfa), erythropoiesis-stimulating agent

EPREX (epoetin alfa), erythropoiesis-stimulating agent Haute Autorité de Santé - EPREX (époétine alfa), agent stimulant l’érythropoïèse Développer la qualité dans le champ sanitaire, social et médico-social Recherche Évaluation & Recommandation La HAS Accréditation & Certification Outils, Guides & Méthodes Agenda Avis sur les Médicaments EPREX (époétine alfa), agent stimulant l’érythropoïèse Substance active (DCI) époétine alfa HEMATOLOGIE - Nouvelle indication Nature de la demande Extension (...) de réponse érythroïde dans une population sélectionnée ne requérant que peu ou pas de transfusion. Mais sa supériorité par rapport au placebo n’a pas été établie sur la normalisation de l’anémie, la réduction du besoin transfusionnel ou sur l’amélioration de la qualité de vie. Comme les autres EPO, l’époétine alfa peut exposer les patients à des effets indésirables rares mais graves : thrombose artérielle, toxicité cutanée sévère et érythroblastopénie, notamment. Service Médical Rendu (SMR

2018 Haute Autorite de sante

7. Recombinant human erythropoietins: very rare risk of severe cutaneous adverse reactions (SCARs)

was reported with each of the following erythropoietins: darbepoetin alfa, epoetin alfa, epoetin beta, and methoxy polyethylene glycol-epoetin beta. The review concluded that 8 reports of SJS and 1 case of TEN were causally associated with r-HuEPOs. More severe cases were observed with long-acting r-HuEPOs (darbepoetin alfa and methoxy polyethylene glycol-epoetin beta). No cases were identified with epoetin zeta; however, the review concluded that the risk of severe cutaneous adverse reactions was a class (...) ); some cases were fatal more severe cases were recorded with long-acting r-HuEPOs (darbepoetin alfa and methoxy polyethylene glycol-epoetin beta) advise patients of the signs and symptoms of severe skin reactions at initiation and instruct them to stop treatment and seek immediate medical attention if they develop widespread rash and blistering; these rashes often occur following fever or flu-like symptoms discontinue all r-HuEPOs permanently in patients who develop severe cutaneous adverse reactions

2018 MHRA Drug Safety Update

8. Darbepoetin Alfa Versus Erythropoietin Alfa for Treatment of Renal Anemia in Patients with Chronic Kidney Disease at the Pre-Dialysis Stage: A Randomized Non-inferiority Trial. (Abstract)

Darbepoetin Alfa Versus Erythropoietin Alfa for Treatment of Renal Anemia in Patients with Chronic Kidney Disease at the Pre-Dialysis Stage: A Randomized Non-inferiority Trial. 30935177 2019 07 23 2019 07 23 0004-5772 67 1 2019 Jan The Journal of the Association of Physicians of India J Assoc Physicians India Darbepoetin Alfa Versus Erythropoietin Alfa for Treatment of Renal Anemia in Patients with Chronic Kidney Disease at the Pre-Dialysis Stage: A Randomized Non-inferiority Trial. 62-66 Mehta (...) 7505585 0004-5772 0 Hematinics 0 Hemoglobins 0 Recombinant Proteins 11096-26-7 Erythropoietin 15UQ94PT4P Darbepoetin alfa Anemia complications drug therapy Darbepoetin alfa pharmacology therapeutic use Erythropoietin pharmacology therapeutic use Hematinics pharmacology therapeutic use Hemoglobins Humans Kidney Failure, Chronic Recombinant Proteins Renal Dialysis Renal Insufficiency, Chronic complications drug therapy 2019 4 3 6 0 2019 4 3 6 0 2019 7 25 6 0 ppublish 30935177

2019 The Journal of the Association of Physicians of India Controlled trial quality: uncertain

9. Darbepoetin alfa (Aranesp) for treatment of anaemia in adults with low or intermediate-1-risk myelodysplastic syndromes

Darbepoetin alfa (Aranesp) for treatment of anaemia in adults with low or intermediate-1-risk myelodysplastic syndromes Darbepoetin alfa (Aranesp) for treatment of anaemia in adults with low or intermediate-1-risk myelodysplastic syndromes | Innovation Observatory toggle menu Menu Search View All Filter by Speciality Filter by Year Filter by Category This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed (...) technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders. > > > Darbepoetin alfa (Aranesp) for treatment of anaemia in adults with low or intermediate-1-risk myelodysplastic syndromes Darbepoetin alfa (Aranesp) for treatment of anaemia in adults with low or intermediate-1-risk myelodysplastic syndromes August 2017 Myelodysplastic syndromes (MDS) are a group of blood disorders, in which the bone marrow does not produce

2017 NIHR Innovation Observatory

10. Low-Dose Erythropoietin in Patients With ST-Segment Elevation Myocardial Infarction (EPO-AMI-II) - A Randomized Controlled Clinical Trial. Full Text available with Trip Pro

Low-Dose Erythropoietin in Patients With ST-Segment Elevation Myocardial Infarction (EPO-AMI-II) - A Randomized Controlled Clinical Trial. Erythropoietin (EPO) has antiapoptotic and tissue-protective effects, but previous clinical studies using high-dose EPO have not shown cardioprotective effects, probably because of platelet activation and a lack of knowledge regarding the optimal dose. In contrast, a small pilot study using low-dose EPO has shown improvement in left ventricular function (...) without adverse cardiovascular events.Methods and Results:We performed a multicenter (25 hospitals), prospective, randomized, double-blind, placebo-controlled, dose-finding study to clarify the efficacy and safety of low-dose EPO in patients with ST-segment elevation myocardial infarction (STEMI) under the Evaluation System of Investigational Medical Care of the Ministry of Health, Labor and Welfare of Japan. In total, 198 STEMI patients with low left ventricular ejection fraction (LVEF <50%) were

2018 Circulation journal : official journal of the Japanese Circulation Society Controlled trial quality: predicted high

11. Cause and Timing of Death and Subgroup Differential Effects of Erythropoietin in the EPO-TBI Study. Full Text available with Trip Pro

Cause and Timing of Death and Subgroup Differential Effects of Erythropoietin in the EPO-TBI Study. The EPO-TBI study randomized 606 patients with moderate or severe traumatic brain injury (TBI) to be treated with weekly epoetin alfa (EPO) or placebo. Six month mortality was lower in EPO treated patients in an analysis adjusting for TBI severity. Knowledge of possible differential effects by TBI injury subtype and acute neurosurgical treatment as well as timing and cause of death (COD (...) ) will facilitate the design of future interventional TBI trials. We defined COD as cerebral (brain death, cerebral death with withdrawal, or death during maximal care) and non-cerebral (death following withdrawal or during maximal care, which had a non-cerebral cause). The study included 305 patients treated with EPO and 297 treated with placebo, with COD recorded in 77 (99%) out of 78 non-survivors. Median time to death in patients dying of cerebral COD was 8 days (interquartile range [IQR] 5-16) compared

2018 Journal of neurotrauma Controlled trial quality: predicted high

12. Effect of deferasirox + erythropoietin vs erythropoietin on erythroid response in Low/Int-1-risk MDS patients: Results of the phase II KALLISTO trial. Full Text available with Trip Pro

Effect of deferasirox + erythropoietin vs erythropoietin on erythroid response in Low/Int-1-risk MDS patients: Results of the phase II KALLISTO trial. Erythropoiesis-stimulating agents (ESAs) remain first-choice to treat symptomatic anemia and delay transfusion dependence in most patients with lower-risk myelodysplastic syndromes (MDS) without del(5q). Deferasirox increased erythroid responses in some lower-risk MDS patients in clinical trials, and adding low-dose deferasirox to ESA treatment (...) may further improve erythroid response.KALLISTO (NCT01868477) was a randomized, open-label, multicenter, phase II study. Lower-risk MDS patients received deferasirox at 10 mg/kg/d (dispersible tablets) or 7 mg/kg/d (film-coated tablets) plus erythropoietin (n = 11), or erythropoietin alone (n = 12) for 24 weeks. The primary endpoint was the between-group difference in erythroid response within 12 weeks.Erythroid response occurred in 27.3% of patients receiving deferasirox plus erythropoietin vs

2018 European journal of haematology Controlled trial quality: uncertain

13. Effect of Topical Erythropoietin (EPO) on palatal wound healing subsequent to Free Gingival Grafting (FGG). Full Text available with Trip Pro

Effect of Topical Erythropoietin (EPO) on palatal wound healing subsequent to Free Gingival Grafting (FGG). Free gingival grafting, the most predictable technique to increase the keratinized gingiva, leaves an open wound on the palate and the resulting discomfort during the healing phase is a significant concern. This study was intended to evaluate the effect of topical erythropoietin on healing of the donor site. Twelve patients lacking an attached gingiva at two sites in the mandible were (...) included. In the test group, 1 mL of gel containing erythropoietin at a concentration of 4,000 IU mL-1 was applied to the donor site, whereas the control group was treated with 2 mL of the gel alone. On the second day after surgery, the same procedure was repeated. H2O2 was used to evaluate the amount of epithelialization. Clinical healing was compared using photographs and direct examination. The EPO group showed significantly better keratinization only on day 21. Comparison of clinical healing based

2018 Brazilian oral research Controlled trial quality: uncertain

14. Switching from Epoetin Alfa (Epogen®) to Epoetin Alfa-Epbx (RetacritTM) Using a Specified Dosing Algorithm: A Randomized, Non-Inferiority Study in Adults on Hemodialysis. Full Text available with Trip Pro

Switching from Epoetin Alfa (Epogen®) to Epoetin Alfa-Epbx (RetacritTM) Using a Specified Dosing Algorithm: A Randomized, Non-Inferiority Study in Adults on Hemodialysis. For patients with anemia undergoing hemodialysis, erythropoiesis-stimulating agents (ESAs) are typically dosed via precise algorithms. Using one such algorithm, we assessed the maintenance of hemoglobin levels in patients switched from epoetin alfa reference product (Epogen®) to epoetin alfa-epbx (RetacritTM; a biosimilar

2018 American journal of nephrology Controlled trial quality: uncertain

15. Comparing Therapeutic Efficacy and Safety of Epoetin Beta and Epoetin Alfa in the Treatment of Anemia in End-Stage Renal Disease Hemodialysis Patients. Full Text available with Trip Pro

Comparing Therapeutic Efficacy and Safety of Epoetin Beta and Epoetin Alfa in the Treatment of Anemia in End-Stage Renal Disease Hemodialysis Patients. Anemia is one of the most prevalent complications in patients with chronic kidney disease, which is believed to be caused by the insufficient synthesis of erythropoietin by the kidney. This phase III study aimed to compare the efficacy and safety of CinnaPoietin® (epoetin beta, CinnaGen) with Eprex® (epoetin alfa, Janssen Cilag) in the treatment (...) of anemia in ESRD hemodialysis patients.In this randomized, active-controlled, double-blind, parallel, and non-inferiority trial, patients were randomized to receive either CinnaPoietin® or Eprex® for a 26-week period. The primary endpoints of this study were to assess the mean hemoglobin (Hb) change during the last 4 weeks of treatment from baseline along with the evaluation of the mean weekly epoetin dosage per kilogram of body weight that was necessary to maintain the Hb level within 10-12 g/dL

2018 American journal of nephrology Controlled trial quality: uncertain

16. EPO does not promote interaction between the erythropoietin and beta-common receptors Full Text available with Trip Pro

EPO does not promote interaction between the erythropoietin and beta-common receptors A direct interaction between the erythropoietin (EPOR) and the beta-common (βc) receptors to form an Innate Repair Receptor (IRR) is controversial. On one hand, studies have shown a functional link between EPOR and βc receptor in tissue protection while others have shown no involvement of the βc receptor in tissue repair. To date there is no biophysical evidence to confirm a direct association of the two (...) receptors either in vitro or in vivo. We investigated the existence of an interaction between the extracellular regions of EPOR and the βc receptor in silico and in vitro (either in the presence or absence of EPO or EPO-derived peptide ARA290). Although a possible interaction between EPOR and βc was suggested by our computational and genomic studies, our in vitro biophysical analysis demonstrates that the extracellular regions of the two receptors do not specifically associate. We also explored

2018 Scientific reports

17. Erythropoietin mimetic peptides and erythropoietin fusion proteins for treating anemia of chronic kidney disease. (Abstract)

Erythropoietin mimetic peptides and erythropoietin fusion proteins for treating anemia of chronic kidney disease. First generation erythropoiesis stimulating agents (ESAs) have short duration of action which requires administration once weekly or greater. Second generation ESAs were developed which have longer duration of action and can be administered one to two times monthly. Erythropoietin (EPO) mimetic peptides (EMPs) activate the EPO receptor but have no structural analogy to EPO, offering (...) the potential for lower cost as they are not biologic drugs. The first approved EMP, peginesatide, was withdrawn from the market within a year of its approval because of fatal anaphylactic reactions. In this review, we summarize recent progress regarding the development of newer, possibly less toxic, EMPs. We also summarize the development of EPO fusion proteins which fuse EPO with a portion of an immunoglobulin molecule or another EPO molecule, achieving a longer duration of action and less frequent

2018 Current Opinion in Nephrology and Hypertension

18. The Erythropoietin Promoter Variant rs1617640 Is Not Associated with Severe Retinopathy of Prematurity, Independent of Treatment with Erythropoietin. (Abstract)

The Erythropoietin Promoter Variant rs1617640 Is Not Associated with Severe Retinopathy of Prematurity, Independent of Treatment with Erythropoietin. In this case-control study, the erythropoietin (EPO) promoter variant s1617640, linked to high intravitreal EPO concentrations and increased risk of diabetic retinopathy, was not associated with severe retinopathy of prematurity. This finding was observed both in infants with and without recombinant EPO administration.Copyright © 2018 Elsevier Inc

2018 Journal of Pediatrics

19. Hyporesponsiveness to Darbepoetin Alfa in Patients With Heart Failure and Anemia in the RED-HF Study (Reduction of Events by Darbepoetin Alfa in Heart Failure): Clinical and Prognostic Associations. Full Text available with Trip Pro

Hyporesponsiveness to Darbepoetin Alfa in Patients With Heart Failure and Anemia in the RED-HF Study (Reduction of Events by Darbepoetin Alfa in Heart Failure): Clinical and Prognostic Associations. A poor response to erythropoiesis-stimulating agents such as darbepoetin alfa has been associated with adverse outcomes in patients with diabetes mellitus, chronic kidney disease, and anemia; whether this is also true in heart failure is unclear.We performed a post hoc analysis of the RED-HF trial (...) (Reduction of Events by Darbepoetin Alfa in Heart Failure), in which 1008 patients with systolic heart failure and anemia (hemoglobin level, 9.0-12.0 g/dL) were randomized to darbepoetin alfa. We examined the relationship between the hematopoietic response to darbepoetin alfa and the incidence of all-cause death or first heart failure hospitalization during a follow-up of 28 months. For the purposes of the present study, patients in the lowest quartile of hemoglobin change after 4 weeks were considered

2018 Circulation. Heart failure

20. Generation of renal Epo-producing cell lines by conditional gene tagging reveals rapid HIF-2 driven Epo kinetics, cell autonomous feedback regulation, and a telocyte phenotype. (Abstract)

Generation of renal Epo-producing cell lines by conditional gene tagging reveals rapid HIF-2 driven Epo kinetics, cell autonomous feedback regulation, and a telocyte phenotype. Erythropoietin (Epo) is essential for erythropoiesis and is mainly produced by the fetal liver and the adult kidney following hypoxic stimulation. Epo regulation is commonly studied in hepatoma cell lines, but differences in Epo regulation between kidney and liver limit the understanding of Epo dysregulation (...) in polycythaemia and anaemia. To overcome this limitation, we have generated a novel transgenic mouse model expressing Cre recombinase specifically in the active fraction of renal Epo-producing (REP) cells. Crossing with reporter mice confirmed the inducible and highly specific tagging of REP cells, located in the corticomedullary border region where there is a steep drop in oxygen bioavailability. A novel method was developed to selectively grow primary REP cells in culture and to generate immortalized clonal

2018 Kidney International

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>